Drug intelligence / Profile preview

crinumin

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes
Administration: Oral, Sublingual, Topical

Overview

Crinumin is a protein identified as an anti-platelet and anti-inflammatory agent. Preclinical studies in rats have demonstrated its ability to significantly reduce carrageenan-induced paw oedema and cotton pellet-induced granuloma formation. Its mechanism involves decreasing the expression of P-selectin, which contributes to reduced platelet activation, and inhibiting NF-κB expression, thereby exerting its anti-inflammatory effects. These findings suggest a potential therapeutic role for crinumin in conditions involving inflammation and platelet aggregation, such as atherosclerosis.

Targets

SELP (P-selectin)Fibrin (Factor Ia)

Beyond the preview

Go deeper on crinumin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on crinumin.

Explore the full profile